← Analysis page  ·  Pieter Slegers hub  ·  Research hub

Actionable insights — Portfolio Update: April 2026 (Part II)

How to run the unpleasant half of a portfolio review: a conviction tier that is really a sell queue, a like-for-like-versus-inflation test, and the difference between a cheap stock and a governance problem.
2026-APR-19 · Compounding Quality (Substack) · Pieter Slegers / Team Compounding Quality · read ↗ · full analysis · transcript
How to read this page: the methods here are all about reviewing what you already own rather than choosing what to buy — which is the harder discipline and the one most process descriptions skip. Written post, so no timestamps.

1. Give every holding a conviction tier, and make the bottom tier a question

The repeatable method
  1. Assign each position to a small number of named tiers — four is enough — and write a one-line definition of each that you would be willing to publish.
  2. Phrase the bottom tier as a question about selling, not as a weaker endorsement. "Medium conviction" invites drift; "should we consider selling these?" forces a decision.
  3. Re-rank on a fixed cadence, and publish the ranking so the previous one can be compared against it.
  4. Review the tiers from the bottom up. The top of a portfolio needs no defending; the bottom is where the returns leak away.
Here: Very Strong / Strong+ / Strong / Medium, with Medium defined as "Should we consider selling these stocks?" Part I covered the top twelve; this issue covers the six below. Within nine days the Medium tier produced exactly one named sell candidate (JDG.L) and two "not sure" verdicts (EVO.ST, NVO) — see 28 April.
Watch for

2. Test a retailer's like-for-like growth against its own input inflation, not against zero

The repeatable method
  1. Take the like-for-like (same-store) sales growth rate the company reports.
  2. Find the relevant price inflation for what it actually sells — food inflation for a grocer, not headline CPI.
  3. Subtract. What remains is real volume growth in the existing estate.
  4. If the answer is negative, the reported growth is coming from prices alone, and every future year depends on new stores rather than on the base business.
  5. Separate that from the store-opening pipeline, which is a different question with different evidence (capex commitments, land, distribution capacity).
Here: DNP.WA reported LFL growth of 4.4% against Polish food inflation of 4.7% — "meaning Dino is effectively losing real volume in existing stores." That single comparison is the stated reason the conviction is Strong rather than Very Strong, and it survives the fact that the company is simultaneously funding a ~45,000 m² distribution centre out of cash.
Watch for

3. Read discretionary capex as management's own forecast, and check how it is funded

The repeatable method
  1. Look for capital commitments that only make sense under a specific growth assumption — distribution capacity, land banks, plant.
  2. Size them and date them: how much, completing when, supporting how many units.
  3. Check the funding source. Cash from operations is a forecast management is willing to fund itself; debt is a forecast someone else is underwriting.
  4. Treat the commitment as harder evidence than the guidance, because it is expensive to reverse.
Here: a Zawiercie hub of ~45,000 m² at ~PLN 150m net, "funded entirely from the company's own cash", completing Q1 2027. The inference drawn is explicit: "You don't invest in a distribution center like this if you're not planning on continuing to grow the number of stores you have."
Watch for

4. Distinguish a cheap stock from a governance problem — the cure for each is different

The repeatable method
  1. When a holding is unusually cheap, ask whether the discount is about the business or about who controls it.
  2. Score the disclosure separately from the numbers: does management explain capital-allocation changes, or announce them and go quiet?
  3. Enumerate the possible explanations for an unexplained action, and note how many of them are good for a minority holder.
  4. If a controlling shareholder is accumulating, model the exit you are actually offered — a takeover premium off a depressed price, not a re-rating to fair value.
  5. Decide in advance what would resolve it: a buyback programme, a stated policy, an independent board response.
Here: EVO.ST at 10.9x earnings and a 10.0% FCF yield — not in dispute. What is in dispute is that the dividend was suspended with only "next steps would follow shortly", and that Kenneth Dart has taken 29%. Four explanations are listed; the developed one is pressure on the founders to sell. The stated fear is the giveaway: "the takeover premium wouldn't be very high" — i.e. the cheapness gets captured by the buyer, not the holder.
Watch for

5. Put a struggling holding on an explicit opportunity-cost test rather than defending it

The repeatable method
  1. Separate the diagnosis ("what went wrong") from the decision ("is this still the best use of the capital").
  2. State the unresolved question in one line — usually "temporary or structural?" — and admit when you cannot answer it.
  3. Rather than forcing an answer, declare the position available: it will be sold if something better is found, not because the thesis is disproved.
  4. Then go and look. The test is only honest if it is paired with an actual search for the alternative.
Here: JDG.L — three external causes named (US research funding cuts, Chinese competition, university customer concentration), then: "The big question is whether these problems are temporary or structural… we are open to selling our position in JDG for another, better opportunity." The search follows immediately: shopping lists on 21 April, 23 April and 26 April, before the sell/buy decision on 28 April.
Watch for

6. Decide with an ownership question, not a valuation, when the uncertainty is about the business

The repeatable method
  1. Do the valuation work anyway — two independent methods if you can.
  2. Then ask the ownership question separately: would I want to own this for the next ten years, knowing what I know?
  3. If the answer is no, treat the valuation as irrelevant. A cheap price is not compensation for a business you do not want.
  4. Write down what would change the answer, so the position is reviewable rather than abandoned.
Here: NVO is shown to be cheap twice over — Terry Smith's rule (8.0% earnings yield + 6% growth = 14%) and Arne Ulland's sum-of-parts, in which the diabetes segment alone (DKK ~200bn revenue, ~42% EBIT margin, 8-12x EV/EBIT) is worth roughly the whole DKK ~235 share price, so "you're getting the entire GLP-1 obesity franchise for free." Neither conclusion is acted on. The question asked instead: "Is Novo Nordisk a company I want to own for the next 10 years? If the answer is no, we might need to look for other, better opportunities."
Watch for

7. Publish the portfolio-versus-index scorecard including the columns you lose

The repeatable method
  1. Build one table comparing your holdings, aggregated, to the index on balance sheet, capital intensity, returns on capital, profitability, growth and valuation.
  2. Include realised performance in the same table, over several horizons.
  3. Do not drop the horizons you lose on. Those are the ones a reader would otherwise have to reconstruct, and they are the reason the review is happening.
  4. Read the combination: better businesses at a lower multiple that have underperformed is a factor drawdown, not a stock-picking failure — but only if the fundamentals in the table are real.
Here: the book wins on fourteen quality measures (interest coverage 39.5x vs 6.8x, ROIC 19.9% vs 10.2%, FCF/net income 265.2% vs 60-90%, forward PE 19.5x vs 21.9x, PEG 1.0x vs 2.2x) and loses on realised returns — 3-year CAGR 5.6% vs 22.3%, 5-year 8.4% vs 13.0% — with only "since IPO" (21.0% vs 8-9%) in its favour. Look-through free cash flow has compounded at 18.1% a year for a decade while the prices have not followed.
Watch for

Methods distilled from the archived Compounding Quality post for personal study. Not investment advice.